Application of Adaptive Design Methodology in Development of a Long-Acting Glucagon-Like Peptide-1 Analog (Dulaglutide): Statistical Design and Simulations

Ítems similars

• An Adaptive, Dose-Finding, Seamless Phase 2/3 Study of a Long-Acting Glucagon-Like Peptide-1 Analog (Dulaglutide): Trial Design and Baseline Characteristics
  per: Geiger, Mary Jane, et al.
  Publicat: (2012)
• A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
  per: Gurung, Tara, et al.
  Publicat: (2015)
• Operational Challenges and Solutions with Implementation of an Adaptive Seamless Phase 2/3 Study
  per: Spencer, Kimberly, et al.
  Publicat: (2012)
• Design, synthesis and crystallization of a novel glucagon analog as a therapeutic agent
  per: Li, Pengyun, et al.
  Publicat: (2007)
• In Vitro and in Vivo Evaluation of Native Glucagon and Glucagon Analog (MAR-D28) during Aging: Lack of Cytotoxicity and Preservation of Hyperglycemic Effect
  per: Ward, W Kenneth, et al.
  Publicat: (2010)